GlassScriptPhysician profile
David Pledger Lyle
NPI 1154339331
$6,763.36
in general payments reported to CMS, 2019-2025
48 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,803 · 2020: $436 · 2021: $198 · 2022: $882 · 2023: $717 · 2024: $1,613 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,444.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $600.27 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $541.97 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $505.41 | 2019-2024 | Qelbree, Tlando, Xyosted |
| Novo Nordisk INC | $494.92 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $493.65 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $441.53 | 2019-2025 | |
| Amgen INC. | $235.99 | 2019-2025 | Otezla, Repatha, Repatha |
| Dexcom, INC. | $229.46 | 2023-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $223.32 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.38 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $200.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $196.95 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $189.17 | 2019-2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $183.64 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $166.55 | 2019-2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $165.46 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.01 | 2019-2022 | |
| Amarin Pharma, INC. | $148.95 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $145.07 | 2019-2023 | Xarelto |
| Daiichi Sankyo INC. | $110.61 | 2019-2025 | Injectafer |
| Exact Sciences Corporation | $108.56 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $104.92 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $93.66 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Stryker Corporation | $83.53 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Clottriever Bold Catheter |
| Sumitomo Pharma America, INC. | $76.01 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $75.74 | 2022 | |
| Arbor Pharmaceuticals, INC. | $73.04 | 2019-2020 | |
| Inari Medical, INC. | $57.91 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kowa Pharmaceuticals America, INC. | $51.17 | 2019 | |
| Allergan, INC. | $44.48 | 2020 | |
| Dynavax Technologies Corporation | $44.11 | 2023-2025 | Heplisav-B |
| Alexion Pharmaceuticals, INC. | $40.16 | 2022 | |
| Genentech USA, INC. | $27.31 | 2019 | |
| Ironwood Pharmaceuticals, INC | $27.24 | 2019 | |
| Edwards Lifesciences Corporation | $22.07 | 2023 | Sapien 3 Ultra Resilia |
| Axsome Therapeutics, INC. | $22.02 | 2025 | Auvelity |
| Tris Pharma INC | $16.96 | 2025 | Dyanavel Xr |
| Si-Bone, INC. | $16.64 | 2019 | |
| Cvrx, INC. | $16.23 | 2024 | Barostim Neo System |
| Optinose US, INC. | $14.72 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.41 | 2024 | Voquezna |
| Evofem Biosciences, INC. | $13.91 | 2022 | |
| Adlon Therapeutics L.P. | $13.79 | 2019 | |
| Halozyme INC | $13.51 | 2023 | |
| Hikma Pharmaceuticals USA | $13.21 | 2022 | |
| Antares Pharma, INC. | $12.66 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.16 | 2022 | |
| Circassia INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.